Nancy King to Humans
This is a "connection" page, showing publications Nancy King has written about Humans.
Connection Strength
0.762
-
King NMP. Key Information in the New Common Rule: Can It Save Research Consent? J Law Med Ethics. 2019 06; 47(2):203-212.
Score: 0.039
-
King NMP, Bishop CE. How Should Physicians Help Patients Understand Unknowns of Nanoparticle-Based Medicines? AMA J Ethics. 2019 04 01; 21(4):E324-331.
Score: 0.039
-
Nageswaran S, Golden SL, Gower WA, King NMP. Caregiver Perceptions about their Decision to Pursue Tracheostomy for Children with Medical Complexity. J Pediatr. 2018 12; 203:354-360.e1.
Score: 0.037
-
King NM. Who's Winning the IRB Wars? The Struggle for the Soul of Human Research. Perspect Biol Med. 2018; 61(3):450-464.
Score: 0.035
-
Hall MA, King NM. Conscience, Courage, and "Consent". Hastings Cent Rep. 2016 Mar-Apr; 46(2):30-2.
Score: 0.031
-
Baker HB, McQuilling JP, King NM. Ethical considerations in tissue engineering research: Case studies in translation. Methods. 2016 Apr 15; 99:135-44.
Score: 0.030
-
King NM. The importance of amicable and productive disagreement. J Med Philos. 2015 Jun; 40(3):286-8.
Score: 0.029
-
King NM. Commentary on Wilson et al. Clin Trials. 2014 Oct; 11(5):530-1.
Score: 0.028
-
King NM, Perrin J. Ethical issues in stem cell research and therapy. Stem Cell Res Ther. 2014 Jul 07; 5(4):85.
Score: 0.028
-
Robeson R, King NM. Loss of possession: concussions, informed consent, and autonomy. J Law Med Ethics. 2014; 42(3):334-43.
Score: 0.027
-
Freedman BI, Fletcher AJ, Sanghani VR, Spainhour M, Graham AW, Russell GB, Cooke Bailey JN, Iltis AS, King NM. Perceptions regarding genetic testing in populations at risk for nephropathy. Am J Nephrol. 2013; 38(6):453-7.
Score: 0.027
-
King NM, Robeson R. Athletes are Guinea pigs. Am J Bioeth. 2013; 13(10):13-4.
Score: 0.025
-
King NM. There's a lot we don't know (and we ought to say so). Am J Bioeth. 2013; 13(12):20-1.
Score: 0.025
-
King NM. Research is care. Hastings Cent Rep. 2012 May-Jun; 42(3):7.
Score: 0.024
-
King NM. Nanomedicine first-in-human research: challenges for informed consent. J Law Med Ethics. 2012; 40(4):823-30.
Score: 0.023
-
King NM, Iltis AS. Introduction: research ethics: reexamining key concerns. J Law Med Ethics. 2012; 40(4):865-6.
Score: 0.023
-
Walker RL, King NM. Biodefense research and the U.S. regulatory structure whither nonhuman primate moral standing? Kennedy Inst Ethics J. 2011 Sep; 21(3):277-310.
Score: 0.023
-
King NM. Benefits, harms, and motives in clinical research. Hastings Cent Rep. 2009 Jul-Aug; 39(4):3.
Score: 0.020
-
King NM, Cohen-Haguenauer O. En route to ethical recommendations for gene transfer clinical trials. Mol Ther. 2008 Mar; 16(3):432-8.
Score: 0.018
-
King NM. The ethics of genetic testing: is more always better? N C Med J. 2007 Mar-Apr; 68(2):112-4.
Score: 0.017
-
Easter MM, Henderson GE, Davis AM, Churchill LR, King NM. The many meanings of care in clinical research. Sociol Health Illn. 2006 Sep; 28(6):695-712.
Score: 0.016
-
King NM. Protection of human subjects and scientific progress: can the two be reconciled? Hastings Cent Rep. 2006 Jan-Feb; 36(1):6-7; author reply 8-9.
Score: 0.015
-
King NM, Henderson GE, Churchill LR, Davis AM, Hull SC, Nelson DK, Parham-Vetter PC, Rothschild BB, Easter MM, Wilfond BS. Consent forms and the therapeutic misconception: the example of gene transfer research. IRB. 2005 Jan-Feb; 27(1):1-8.
Score: 0.014
-
Henderson GE, Davis AM, King NM. Vulnerability to influence: a two-way street. Am J Bioeth. 2004; 4(3):50-2; discussion W32.
Score: 0.013
-
King NM. Accident & desire. Inadvertent germline effects in clinical research. Hastings Cent Rep. 2003 Mar-Apr; 33(2):23-30.
Score: 0.013
-
King NM. The line between clinical innovation and human experimentation. Seton Hall Law Rev. 2003; 32(3):571-80.
Score: 0.012
-
King NM. RAC oversight of gene transfer research: a model worth extending? J Law Med Ethics. 2002; 30(3):381-9.
Score: 0.012
-
Bailey DB, Gehtland LM, Lewis MA, Peay H, Raspa M, Shone SM, Taylor JL, Wheeler AC, Cotten M, King NMP, Powell CM, Biesecker B, Bishop CE, Boyea BL, Duparc M, Harper BA, Kemper AR, Lee SN, Moultrie R, Okoniewski KC, Paquin RS, Pettit D, Porter KA, Zimmerman SJ. Early Check: translational science at the intersection of public health and newborn screening. BMC Pediatr. 2019 07 17; 19(1):238.
Score: 0.010
-
Andrews JE, Moore JB, Weinberg RB, Sissine M, Gesell S, Halladay J, Rosamond W, Bushnell C, Jones S, Means P, King NMP, Omoyeni D, Duncan PW. Ensuring respect for persons in COMPASS: a cluster randomised pragmatic clinical trial. J Med Ethics. 2018 08; 44(8):560-566.
Score: 0.009
-
Shepherd L, Macklin R, King NM, Dreger A, Wages NA. Informed Consent for Research on Medical Practices. Ann Intern Med. 2015 Nov 03; 163(9):725.
Score: 0.008
-
Friedmann T, Jonlin EC, King NMP, Torbett BE, Wivel NA, Kaneda Y, Sadelain M. ASGCT and JSGT Joint Position Statement on Human Genomic Editing. Mol Ther. 2015 Aug; 23(8):1282.
Score: 0.007
-
Macklin R, Shepherd L, Dreger A, Asch A, Baylis F, Brody H, Churchill LR, Coleman CH, Cowan E, Dolgin J, Downie J, Dresser R, Elliott C, Epright MC, Feder EK, Glantz LH, Grodin MA, Hoffman W, Hoffmaster B, Hunter D, Iltis AS, Kahn JD, King NM, Kraft R, Kukla R, Leavitt L, Lederer SE, Lemmens T, Lindemann H, Marshall MF, Merz JF, Miller FH, Mohrmann ME, Morreim H, Nass M, Nelson JL, Noble JH, Reis E, Reverby SM, Silvers A, Sousa AC, Spece RG, Strong C, Swazey JP, Turner L. The OHRP and SUPPORT--another view. N Engl J Med. 2013 Jul 11; 369(2):e3.
Score: 0.006
-
Churchill LR, King NM, Henderson GE. Why we should continue to worry about the therapeutic misconception. J Clin Ethics. 2013; 24(4):381-6.
Score: 0.006
-
Corrigan-Curay J, Cohen-Haguenauer O, O'Reilly M, Ross SR, Fan H, Rosenberg N, Somia N, King N, Friedmann T, Dunbar C, Aiuti A, Naldini L, Baum C, von Kalle C, Kiem HP, Montini E, Bushman F, Sorrentino BP, Carrondo M, Malech H, Gahrton G, Shapiro R, Wolff L, Rosenthal E, Jambou R, Zaia J, Kohn DB. Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. Mol Ther. 2012 Jun; 20(6):1084-94.
Score: 0.006
-
Fatehi L, Wolf SM, McCullough J, Hall R, Lawrenz F, Kahn JP, Jones C, Campbell SA, Dresser RS, Erdman AG, Haynes CL, Hoerr RA, Hogle LF, Keane MA, Khushf G, King NM, Kokkoli E, Marchant G, Maynard AD, Philbert M, Ramachandran G, Siegel RA, Wickline S. Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field. J Law Med Ethics. 2012; 40(4):716-50.
Score: 0.006
-
Henderson GE, Juengst ET, King NM, Kuczynski K, Michie M. What research ethics should learn from genomics and society research: lessons from the ELSI Congress of 2011. J Law Med Ethics. 2012; 40(4):1008-24.
Score: 0.006
-
Kent A, King NM, Cohen-Haguenauer O. Toward a proportionate regulatory framework for gene transfer: a patient group-led initiative. Hum Gene Ther. 2011 Feb; 22(2):126-34.
Score: 0.005
-
King NM, Henderson G. Treatments of last resort: informed consent and the diffusion of new technology. Mercer Law Rev. 1991; 42(3):1007-50.
Score: 0.005
-
Hall MA, Friedman JY, King NM, Weinfurt KP, Schulman KA, Sugarman J. Commentary: Per capita payments in clinical trials: reasonable costs versus bounty hunting. Acad Med. 2010 Oct; 85(10):1554-6.
Score: 0.005
-
Hall MA, King NM, Perdue LH, Hilner JE, Akolkar B, Greenbaum CJ, McKeon C. Biobanking, consent, and commercialization in international genetics research: the Type 1 Diabetes Genetics Consortium. Clin Trials. 2010; 7(1 Suppl):S33-45.
Score: 0.005
-
Weinfurt KP, Hall MA, King NM, Friedman JY, Schulman KA, Sugarman J. Disclosure of financial relationships to participants in clinical research. N Engl J Med. 2009 Aug 27; 361(9):916-21.
Score: 0.005
-
Henderson GE, Churchill LR, Davis AM, Easter MM, Grady C, Joffe S, Kass N, King NM, Lidz CW, Miller FG, Nelson DK, Peppercorn J, Rothschild BB, Sankar P, Wilfond BS, Zimmer CR. Clinical trials and medical care: defining the therapeutic misconception. PLoS Med. 2007 Nov 27; 4(11):e324.
Score: 0.004
-
Kipnis K, King NM, Nelson RM. An open letter to institutional review boards considering Northfield Laboratories' PolyHeme trial. Am J Bioeth. 2006 May-Jun; 6(3):18-21.
Score: 0.004
-
Kipnis K, King NM, Nelson RM. Trials and errors: barriers to oversight of research conducted under the emergency research consent waiver. IRB. 2006 Mar-Apr; 28(2):16-9.
Score: 0.004
-
Havighurst CC, King NM. Liver transplantation in Massachusetts: public policymaking as morality play. Indiana Law Rev. 1986; 19(4):955-87.
Score: 0.004
-
Henderson GE, Easter MM, Zimmer C, King NM, Davis AM, Rothschild BB, Churchill LR, Wilfond BS, Nelson DK. Therapeutic misconception in early phase gene transfer trials. Soc Sci Med. 2006 Jan; 62(1):239-53.
Score: 0.004
-
Henderson GE, Davis AM, King NM, Easter MM, Zimmer CR, Rothschild BB, Wilfond BS, Nelson DK, Churchill LR. Uncertain benefit: investigators' views and communications in early phase gene transfer trials. Mol Ther. 2004 Aug; 10(2):225-31.
Score: 0.003
-
Churchill LR, Nelson DK, Henderson GE, King NM, Davis AM, Leahey E, Wilfond BS. Assessing benefits in clinical research: why diversity in benefit assessment can be risky. IRB. 2003 May-Jun; 25(3):1-8.
Score: 0.003
-
King NM. Health policy--ensuring informed consent in human experimentation: a comparison of the approaches of two states. North Carol Law Rev. 1979 Oct; 58(1):137-52.
Score: 0.002